A University of Alabama at Birmingham Heersink School of Medicine-led study suggests that first-time transient ischemic ...
The following is a summary of “Association between impaired brachial flow-mediated dilation and early neurological ...
The following is a summary of “Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion,” published in the February ...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed ...
For patients with acute ischemic stroke (AIS) whose symptoms began 4.5 to 24 hours earlier, alteplase is associated w ...
An update from Diamedica Therapeutics ( ($DMAC) ) is now available. On February 20, 2025, DiaMedica Therapeutics appointed Daniel J. O’Connor to ...
DiaMedica Therapeutics (DMAC) announced the peer-reviewed publication entitled: “Recombinant human tissue kallikrein-1 for treating acute ...
Leading Spanish neuroradiologists presented a unique multicentre registry to boost stroke treatment at the 12th Triángulo ...
Researchers found that the percentage of patients achieving a score of 0 or 1 on the modified Rankin scale at 90 days was 40.3 and 26.3% in the alteplase and standard medical treatment groups ...
In animal studies of acute stroke, bradykinin B2 receptor expression on brain endothelial cells in the ischemic region increased 36-fold. In this environment, newly generated bradykinin from DM199 ...